SERUM PNEUMOCOCCAL IgG LEVELS IN INFANTS OF MOTHERS VACCINATED WITH PNEUMOCOCCAL CONJUGATE VACCINE IN THE THIRD TRIMESTER

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR202102724115194

Enrollment

110

Registered

2021-02-01

Start date

2021-01-21

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumococcal Disease

Interventions

TTCONTROL

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Gestational age from 30weeks 0 days to 34 weeks 6 days. Pregnant women aged 18 to 40 years An uncomplicated pregnancy. No identified risk for complicated labor. No previous history of preterm delivery (< 37 completed weeks). No previous history of delivery of neonate with major congenital malformation.

Exclusion criteria

Exclusion criteria: Major or lethal congenital fetal anomaly. Intrauterine fetal death. Pregnancy which has not been dated by obstetric ultrasound. Previous history of vaccination with the pneumococcal polysaccharide or conjugate vaccines. Known allergies to any constituents of vaccine.

Design outcomes

Primary

Measure	Time frame
Geometric mean concentration of Pneumococcal-specific IgG in cord blood of newborns;Geometric mean concentration of Pneumococcal-specific IgG in serum of infants whose mothers received Pneumococcal Conjugate Vaccine in the third trimester at 6 weeks of age.	—

Secondary

Measure	Time frame
Cord blood concentration of Pneumococcal-specific IgG in relation to duration of vaccination to delivery interval. ;Adverse events such vaccination site pain, fever, seizures, and pregnancy outcomes such as preterm birth, fetal loss, etc	—

Countries

Nigeria

Contacts

Public ContactAyodeji Akinola

Resident Doctor

daygee22@hotmail.com+2347080146586

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026